Frequency and Severity of Hypoglycemia in Type 2 Diabetes Mellitus Patients Treated with a Sulfonylurea-Based Regimen at University-Affiliated Hospitals in Korea: The Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin.Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lower-ing medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c <7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respec-tively. Several reported hypoglycemia frequency as 1–2 times over the last 6 months. The mean number of very severe hypoglyce-mia episodes was 3.5±5.5.Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
Abstract
Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin.Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lower-ing medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c <7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respec-tively. Several reported hypoglycemia frequency as 1–2 times over the last 6 months. The mean number of very severe hypoglyce-mia episodes was 3.5±5.5.Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
참고문헌 (21)
- International Diabetes Federation, "IDF diabetes atlas" (2011), International Diabetes Federation
- Zenari L, "What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?", Diabetes Obes Metab, 15(Suppl 2), pp.17~25 (2013)
- Charpentier G, "Management of drugs affecting blood glucose in diabetic patients with renal failure", Diabetes Metab, 26(Suppl 4), pp.73~85 (2000)
- Evans JM, "Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes : a comparison of patients treated with sulfonylureas and metformin", Diabetologia, 49, pp.930~936 (2006)
- Simpson SH, "Doseresponse relation between sulfonylurea drugs and mortality in type 2diabetes mellitus : a population-based cohort study", CMAJ, 174, pp.169~174 (2006)
- Banarer S, "Hypoglycemia in type 2 diabetes", Med Clin North Am, 88, pp.1107~1116 (2004)
- Del Prato S, "The place of sulfonylureas in the therapy for type 2 diabetes mellitus", Metabolism, 55(5 Suppl 1), pp.S20~S27 (2006)
- Miller CD, "Hypoglycemia in patients with type 2 diabetes mellitus", Arch Intern Med, 161, pp.1653~1659 (2001)
- Ben-Ami H, "Drug-induced hypoglycemic coma in 102 diabetic patients", Arch Intern Med, 159, pp.281~284 (1999)
- Browne DL, "What do patients with diabetes know about their tablets", Diabet Med, 17, pp.528~531 (2000)
- UBcare Co. Ltd, "UBIquitous STatistics (UBIST) data 2009", UBcare Co. Ltd, ~ (2009)
- American Diabetes Association, "Standards of medical care in diabetes--2011", Diabetes Care, 34(Suppl 1), pp.S11~S61 (2011)
- Alvarez Guisasola F, "Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study", Diabetes Obes Metab, 10(Suppl 1), pp.25~32 (2008)
- UK Hypoglycaemia Study Group, "Risk of hypoglycaemia in types 1 and 2 diabetes : effects of treatment modalities and their duration", Diabetologia, 50, pp.1140~1147 (2007)
- Chan SP, "Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-life effectiveness and care patterns of diabetes management : the RECAP-DM study", Diabetes Res Clin Pract, 89, pp.e30~2 (2010)
- Wild D, "A critical review of the literature on fear of hypoglycemia in diabetes : Implications for diabetes management and patient education", Patient Educ Couns, 68, pp.10~15 (2007)
- Alvarez Guisasola F, "Glycaemic control among patients with type 2 diabetes mellitus in seven European countries : findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management(RECAP-DM)Study", Diabetes Obes Metab, 10(Suppl 1), pp.8~15 (2008)
- Amiel SA, "Hypoglycaemia in type 2 diabetes", Diabet Med, 25, pp.245~254 (2008)
- Nattrass M, "Review of prandial glucose regulation with repaglinide:a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes?", Int J Obes Relat Metab Disord, 24(Suppl 3), pp.S21~S31 (2000)
- Coteur G, "Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease", Aliment Pharmacol Ther, 29, pp.1032~1041 (2009)
- Shikiar R, "The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients : results of a phase II study", Health Qual Life Outcomes, 4, pp.71~ (2006)